Alphabet's Isomorphic Labs raises $2.1 billion to scale AI drug discovery toward clinical trials
Isomorphic Labs, the AI drug research company led by DeepMind co-founder Demis Hassabis, has closed a $2.1 billion Series B round led by Thrive Capital. The funding will go toward expanding its in-house platform IsoDDE and advancing drug candidates toward clinical trials.
Alphabet's Isomorphic Labs raises $2.1 billion to scale AI drug discovery toward clinical trials
Report an error
The correction channel is not available yet. You can copy the article reference below for later.
Correction instructionsSummary only
Under the source content permission, this page provides an editorial summary, key points, and a link to the original article.